Home » Topics » Disease categories and therapies » Ocular

Ocular
RSS

NanoViricides enters nondisclosure agreements for nanoviricide drug candidate in EKC

May 29, 2008

Recent patents describe novel treatment alternatives for eye disorders

May 26, 2008

Inspire receives milestone payment of USD 1.25 million from Santen

May 20, 2008

Lpath initiate phase I clinical trial for iSONEP in patients with AMD

May 19, 2008

Placental growth factor blockade useful in mouse models of CNV

May 16, 2008

arGentis licenses ARG-103 for dry eye syndrome from Southern College of Optometry

May 16, 2008

Phase I study of Nexagon for healing after laser eye surgery recruiting patients

May 15, 2008

Alimera initiates enrollment in clinical trial of Medidur FA in conjunction with Lucentis

May 15, 2008

Regeneron's angiopoietin-2 neutralizing antibody promotes CNV regression

May 14, 2008

Spotlight on ranibizumab phase III trials for AMD

May 14, 2008

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 11, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Italy’s Angelini pays $4.1B cash for rare disease specialist Catalyst
BioWorld
Italian family-owned Angelini Pharma SpA is making its first move into the U.S. market, acquiring rare diseases specialist Catalyst Pharma Inc. in an all-cash...